Cogent Biosciences, Inc.

NasdaqGS:COGT 주식 보고서

시가총액: US$1.0b

Cogent Biosciences 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Andy Robbins

최고 경영자

US$7.9m

총 보상

CEO 급여 비율8.3%
CEO 임기4.1yrs
CEO 소유권n/a
경영진 평균 재임 기간3.8yrs
이사회 평균 재임 기간4.3yrs

최근 관리 업데이트

Recent updates

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Sep 04
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences: Inflection Year Directly Ahead

Jun 23

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

May 22
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst

Feb 14

Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 27
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 20
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Mar 05
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 18
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Cogent Biosciences: What's Ahead

Sep 13

Cogent Biosciences: APEX Data Was Interesting, But We Need More

Jun 26

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 10
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Cogent Biosciences names new chief legal officer

May 03

What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Mar 17
What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Cogent Biosciences gets Piper Sandler nod on Kiq acquisition

Dec 23

Cogent Biosciences prices upsized $100M equity offering

Dec 02

Cogent Bio launches $60M equity offering, shares down 7%

Nov 30

Cogent Bio reports data from PLX9486 combo trial in GIST patients

Nov 18

Cogent Biosciences EPS misses by $4.91

Nov 09

CEO 보상 분석

Andy Robbins 의 보수는 Cogent Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$242m

Jun 30 2024n/an/a

-US$227m

Mar 31 2024n/an/a

-US$212m

Dec 31 2023US$8mUS$656k

-US$192m

Sep 30 2023n/an/a

-US$178m

Jun 30 2023n/an/a

-US$157m

Mar 31 2023n/an/a

-US$148m

Dec 31 2022US$4mUS$624k

-US$140m

Sep 30 2022n/an/a

-US$126m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$3mUS$593k

-US$72m

Sep 30 2021n/an/a

-US$163m

Jun 30 2021n/an/a

-US$194m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$18mUS$102k

-US$179m

보상 대 시장: Andy 의 총 보상 ($USD 7.90M )은 US 시장( $USD 3.15M ).

보상과 수익: 회사가 수익성이 없는 동안 Andy 의 보상이 증가했습니다.

CEO

Andy Robbins (48 yo)

4.1yrs

테뉴어

US$7,898,772

보상

Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director at of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was...

리더십 팀

이름위치테뉴어보상소유권
Andrew Robbins
President4.1yrsUS$7.90m데이터 없음
John Robinson
Chief Scientific Officer3.6yrsUS$2.98m0%
$ 0
Jessica Sachs
Chief Medical Officer5.4yrsUS$3.00m0.0012%
$ 11.9k
John Green
CFO & Principal Accounting Officer4.3yrsUS$2.14m데이터 없음
Brad Barnett
Chief Technology Officer4yrs데이터 없음데이터 없음
Christi Waarich
Senior Director of Investor Relationsno data데이터 없음데이터 없음
Evan Kearns
Chief Legal Officer & Corporate Secretary3.5yrs데이터 없음데이터 없음
Erin Schellhammer
Chief People Officerno data데이터 없음데이터 없음
Dana Martin
Senior VP of Medical Affairs & Chief Patient Officerno data데이터 없음데이터 없음
Brad Fell
Senior Vice President of Chemistryno data데이터 없음데이터 없음
Rachael Easton
VP & Head of Clinical Development2yrs데이터 없음데이터 없음
Ben Exter
Senior VP and Head of Regulatory & Pharmacovigilanceless than a year데이터 없음데이터 없음

3.8yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: COGT 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Andrew Robbins
President4.1yrsUS$7.90m데이터 없음
Arlene Morris
Independent Director5.3yrsUS$345.49k0%
$ 0
Matthew Ros
Independent Director5.3yrsUS$336.69k0%
$ 0
Todd Shegog
Independent Director3.8yrsUS$345.80k0%
$ 0
Kwok-Kin Wong
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Karen Jean Ferrante
Independent Director6.8yrsUS$340.37k0%
$ 0
Michael Vasconcelles
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Ryan Corcoran
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Christopher Cain
Independent Director4.3yrsUS$341.36k0%
$ 0
Peter Harwin
Independent Chairman of the Board4.3yrsUS$364.55k0%
$ 0
Srdan Verstovsek
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Sylvia Adams
Member of Scientific Advisory Board1.8yrs데이터 없음데이터 없음

4.3yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: COGT 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.